Low Serum Levels of Uric Acid are Associated With Development of Poststroke Depression

Yingying Gu, MD, Bin Han, MD, Liping Wang, MD, Yaling Chang, MD, Lin Zhu, MD, Wenwei Ren, MD, Mengjiao Yan, MD, Xiangyang Zhang, PhD, and Jincai He, MD

Abstract: Poststroke depression (PSD) is a frequent complication of stroke that has been associated with poorer outcome of stroke patients. This study sought to examine the possible association between serum uric acid levels and the development of PSD.

We recruited 196 patients with acute ischemic stroke and 100 healthy volunteers. Serum uric acid levels were tested by uricase-PAP method within 24 hr after admission. Neuropsychological evaluations were conducted at 3-month poststroke. The 17-item Hamilton Depression Scale was used to assess depressive symptoms. Diagnosis of PSD was made in accordance with DSM-IV criteria for depression. Multivariate analyses were conducted using logistic regression models.

Fifty-six patients (28.6%) were diagnosed as having PSD at 3 months. PSD patients showed significantly lower levels of uric acid at baseline as compared to non-PSD patients (237.02 vs 239.0 and 238.1 μmol/L, P = 0.0001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001). In multivariate analyses, uric acid levels (≤239.0 and ≥328.1 μmol/L) were independently associated with the development of PSD (OR, 7.76; 95% confidence interval [CI], 2.56–23.47, P < 0.001).

Oxidative stress characterized by as an imbalance between oxidants and antioxidants that results from overproduction of free radicals and reactive oxygen species, can affect various physiological functions, including the central nervous system. A fast growing body of evidence suggests the involvement of oxidative stress in the pathophysiology of depression. Acute ischemic stroke leads to increased levels of oxidative stress and decreased levels of antioxidants, including uric acid. Notably, it is hypothesized that increased oxidative stress in cerebral tissues is implicated in the pathophysiology of PSD. Additionally, serum uric acid may be neuroprotective in acute ischemic stroke patients and may contribute to stroke outcome. Considering the involvement of uric acid in stroke as well as depression, we hypothesize that serum uric acid levels are related to the development of PSD.
dementia or significant cognitive impairment, Parkinson’s disease, tumor; subjects with a history of any psychiatric illness; subjects with severe aphasia, decreased level of consciousness, visual or auditory impairment; subjects with concomitant renal impairment. Meanwhile, 100 healthy volunteers without a history of psychiatric or renal impairment were recruited from a health survey. They were of similar gender and age distribution to the stroke patients. This study protocol was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and approved by the Medical Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from all patients.

Clinical Variables
At admission, demographic data and history of conventional vascular risk factors were recorded. Stroke severity was assessed by trained neurologists using the National Institutes of Health Stroke Scale (NIHSS) within 24 hr of admission. Functional outcome was evaluated by the modified Rankin Scale (mRS) and the Barthel Index (BI) at discharge. Cranial computerized and magnetic resonance imaging were performed within 24 to 72 hr after admission in order to assess the site of the brain infarct. Blood sample was taken from all patients during 24 hr of admission. Serum uric acid was measured using uricase-PAP method in our hospital biochemistry department. The serum level ranging from 208 to 428 µmol/L in male patients and ranging from 155 to 357 µmol/L in female patients was categorized as normal. Serum uric acid was recorded and divided into 3 tertiles (≤239.0, 239.1–328.0, and ≥328.1 µmol/L), as the raw uric acid data were skewed.

Assessment of PSD
Depression estimations were performed by a neurologist/psychiatrist who was blind to the laboratory results of stroke patients at 3 months after stroke. Stroke survivals should complete the 17-Hamilton Rating Scale for Depression (17-HAMD) at 3-month follow-up. Clinical depression was diagnosed on the basis of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria performed algorithms depended on psychiatric interview and neuropsychiatric examination.

Statistical Analysis
The results were indicated as percentages for categorical variables, while continuous variables depending on their normal distribution were expressed as mean ± standard deviation (SD) or median (interquartile range, IQR). The Chi-squared test was employed for proportions and the normally distributed variables was compared using Student t test and analysis of variance (ANOVA), while the Mann–Whitney U test was employed for the asymmetrically distributed variables. Spearman’s rank correlation was performed for bivariate correlation. The influence of serum uric acid levels on PSD was estimated by binary logistic regression analysis, after adjusting for potential confounding variables. Results were indicated as adjusted odds ratios (ORs) (95% confidence intervals, CIs). All statistical analysis was used SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL). Statistical significance was identified as P < 0.05.

RESULTS

Baseline Characteristics of Study Samples
The study cohort consisted of 251 individuals entry criteria. By the time of 3-month poststroke hospital follow-up, 2.0% (n = 5) had passed away and 19.9% (n = 50) declined due to missing data, leaving 196 patients. In this study population, 33.7% were female and the average age was 61.16 ± 10.10 years. Patients excluded from this study had a higher NIHSS score when compared with patients included in the study (z = −4.51, P < 0.001). There were no significant differences in age (t = −0.23, P = 0.82) and sex (χ² = 0.08, P = 0.76).

Main Findings
Of the 196 subjects who formed the study sample, 56 (28.6%, 24 men, 32 women) were diagnosed with PSD. The average hospitalization mean (±SD) time per patient was 10.40 ± 3.25 days. The mean (±SD) uric acid levels at baseline were significantly lower in stroke patients as compared to normal controls (288.51 ± 69.57 vs 344.46 ± 88.06 µmol/L, t = 5.53, P < 0.001). There was a positive correlation between serum levels of uric acid and age of the patients (r = 0.53, P < 0.001; Fig. 1A). There was a negative correlation between serum levels of uric acid and HAMD scores (r = −0.51, P < 0.001; Figure 1B). There was a significant difference in serum uric acid levels between men and women (t = −4.60, P < 0.001). The PSD patients were younger (z = −2.56, P = 0.01) and had a more severe stroke (z = −3.82, P < 0.001) and poorer functional outcomes (z = −6.60, P < 0.001). No association was found between lesion location and PSD (Table 1).

FIGURE 1. Correlation between serum uric acid levels and other predictors. (A) Correlation between the age of patients and serum uric acid levels; r[sparan] = 0.528, P < .001. (B) Correlation between the Hamilton Depression Scale (HAMD) score and serum uric acid levels; r[sparan] = −0.507, P < .001.
Serum median uric acid levels were significantly decreased at admission in PSD patients than non-PSD patients (237.02 ± 43.43 vs. 309.10 ± 67.44 μmol/L, t = −8.86, P < 0.001). Additionally, significant differences were observed between the PSD patients and stroke patients without depression in uric acid level tertiles ($\chi^2 = 44.39, P < 0.001$). Indeed, the proportion of serum uric acid in the lowest tertile ($\leq 239.0 \mu mol/L$) was significantly elevated in the PSD patients ($\chi^2 = 36.75, P < 0.001$), meanwhile the proportion of serum uric acid in the highest tertile ($\geq 328.1 \mu mol/L$) was significantly decreased in the PSD patients ($\chi^2 = 21.18, P < 0.001$; Table 1). With all stroke subjects taken as a whole, stroke patients with depression presence as a dependent variable, factors with $P < 0.10$ in the univariate analysis as independent variables in the logistic analysis. Results found that uric acid levels ($\leq 239.0$ and $\geq 328.1 \mu mol/L$) were independently associated with the presence of PSD (OR, 7.76; 95% CI, 2.56–23.47, $P < 0.001$ and OR, 0.05; 95% CI, 0.01–0.43, $P = 0.01$, respectively). Moreover, the mRS scores at discharge were significantly associated with the presence of PSD 3 months after stroke (OR, 2.49; 95% CI, 1.20–5.16, $P = 0.01$; Table 2).

### Table 1. Clinical and Demographic Characteristics of the Samples Under Study

| Variables | PSD Patients (n = 56) | Non-PSD (n = 140) | T Value | P     |
|-----------|-----------------------|-------------------|---------|-------|
| **Demographic characteristics** | | | | |
| Sex, M/F | 32/24 | 98/42 | 2.96 | 0.09 |
| Age, yr, mean ± SD | 58.29 ± 9.50 | 62.31 ± 10.14 | −2.56 | 0.01 |
| Education, yr, median (IQR) | 4 (0–16) | 5 (0–16) | 0.50 |
| BMI, kg/m², mean ± SD | 23.67 ± 3.15 | 24.50 ± 3.31 | 0.11 |
| Marital states, married | 53 (94.6) | 126 (90.0) | 0.30 |
| **Lesion location** | | | | 0.89 |
| Frontal lobe | 9 (16.1) | 21 (15.0) |
| Parietal lobe | 6 (10.7) | 15 (10.7) |
| Temporal lobe | 4 (7.1) | 13 (9.3) |
| Occipital lobe | 2 (3.6) | 8 (5.7) |
| Basal ganglia | 17 (30.4) | 32 (22.9) |
| Brainstem | 4 (7.1) | 15 (10.7) |
| Cerebellum | 3 (5.4) | 13 (9.3) |
| Other | 11 (19.6) | 23 (16.4) |
| **Vascular risk factors** | | | | |
| History of hypertension | 44 (78.6) | 94 (67.1) | 1.11 |
| History of diabetes | 25 (44.6) | 46 (32.9) | 0.12 |
| History of hyperlipidemia | 39 (69.6) | 90 (64.3) | 0.48 |
| CAD | 6 (10.7) | 8 (5.7) | 0.22 |
| History of stroke | 6 (10.7) | 10 (7.1) | 0.41 |
| Current smoking | 14 (25.0) | 49 (35.0) | 0.18 |
| Current drinking | 13 (23.2) | 44 (31.4) | 0.25 |
| **Neuropsychological function** | | | | |
| NIHSS score median (IQR) | 4 (0–11) | 2 (0–12) | −3.82 | <0.001 |
| BI score median (IQR) | 90 (50–100) | 100 (60–100) | 6.62 | <0.001 |
| mRS score median (IQR) | 2 (0–3) | 0 (0–3) | −6.60 | <0.001 |
| **Clinical and laboratory variables** | | | | |
| SBP, mm Hg, mean ± SD | 162.04 ± 22.00 | 155.93 ± 22.15 | 1.75 | 0.08 |
| DBP, mm Hg, mean ± SD | 89 (64–113) | 85 (55–124) | 0.51 |
| TC, mmol/L, median (IQR) | 1.19 (0.73–6.01) | 1.19 (0.65–9.54) | 0.20 |
| TG, mmol/L, mean ± SD | 5.03 ± 1.09 | 4.81 ± 1.14 | 0.21 |
| LDL, mmol/L, mean ± SD | 3.00 ± 0.92 | 2.72 ± 0.92 | 1.87 | 0.06 |
| HDL, mmol/L, median (IQR) | 1.17 (0.70–2.16) | 1.13 (0.62–2.65) | 0.51 |
| FBG, mmol/L, median (IQR) | 5.1 (2.5–13.1) | 5.2 (3.1–13.5) | 0.49 |
| HbA1c, %, median (IQR) | 5.9 (5.0–14.9) | 6.1 (4.5–12.4) | 0.22 |
| BUN, mmol/L, median (IQR) | 4.9 (1.9–7.4) | 5.0 (1.9–7.4) | 0.63 |
| Cr, μmol/L, median (IQR) | 70.0 (45.0–90.0) | 71.0 (36.0–90.0) | 0.42 |
| **Uric acid** | | | | |
| Tertile 1 | 31 (55.4) | 19 (13.6) | 44.39 | <0.001 |
| Tertile 2 | 24 (42.9) | 75 (53.6) | 36.75 | <0.001 |
| Tertile 3 | 1 (1.8) | 46 (32.9) | 1.84 | 0.18 |

Values are shown as number (percentage) or as medians (IQR) and means (±SD). BI = Barthel Index, BMI = body mass index, BUN = urea nitrogen, CAD = coronary artery disease, Cr = creatinine, DBP = diastolic blood pressure, FBG = fasting blood glucose, HbA1C (%) = glycolated hemoglobin, HDL = high-density lipoprotein, IQR = interquartile range, LDL = low-density lipoprotein, mRS = modified Rankin Scale, NIHSS = National Institutes of Health Stroke Scale, PSD = poststroke depression, SBP = systolic blood pressure, SD = standard deviation, TC = total cholesterol, TG = triglyceride.
TABLE 2. Adjusted OR of Depression for Serum Uric Acid Levels at Admission in the Stroke Patients

| Variables   | OR   | 95% CI          | P     |
|-------------|------|-----------------|-------|
| Uric acid   |      |                 |       |
| Tertile 1   | 7.76 | (2.56–23.47)    | <0.001|
| Tertile 3   | 0.05 | (0.01–0.43)     | 0.01  |
| Sex         | 0.25 | (0.09–0.74)     | 0.01  |
| Age         | 0.26 |                 |       |
| SBP         | 0.12 |                 |       |
| LDL         | 0.64 |                 |       |
| NHISS score | 0.83 |                 |       |
| mRS score   | 2.49 | (1.20–5.16)     | 0.01  |
| BI score    | 0.25 |                 |       |

BI = Barthel Index, CI = confidence interval, LDL = low-density lipoprotein, mRS = modified Rankin Scale, NHISS = National Institutes of Health Stroke Scale, OR = odds ratio, SBP = systolic blood pressure.

DISCUSSION

To our knowledge, this is by far the first study explored the possible relationship between serum uric acid levels at admission and the presence of depression 3 months after stroke. Our results indicated that uric acid is a powerful biological marker of presence of PSD at 3 months after stroke. Therefore, it may be used as a useful novel therapeutic target for the treatment of PSD.

In the present study, we found that 28.6% of stroke patients were diagnosed as having major depression at 3 months after stroke, which is consistent with the results of recent researches. Currently, despite the already vast literature, it remains difficult to determine the true prevalence of PSD, possibly due to the different study designs, methods used to diagnose PSD, time of evaluation, and source of patient recruitment, together with the racial disparities in PSD detection.

Serum uric acid levels are affected by both age and gender. In the present study, we found that men had higher serum uric acid levels when compared to women. There was a significant positive correlation between age of stroke patients and serum uric acid levels. These results broadly agree with previous studies. Furthermore, serum levels of uric acid at admission were found to be significantly lower in stroke patients than in normal subjects, in agreement with previous reports.

Importantly, we found that serum uric acid levels at admission were independently associated with the development of PSD at 3 months after stroke. As mentioned earlier, a fast growing body of studies have reported low uric acid levels in patients with psychiatric disorders, including depression. They also found that serum levels of uric acid in patients with depression normalized after treatment with antidepressants. In addition, a significant inverse relationship between serum uric acid levels and Zung Self-Rating Depression Scale scores was observed in a population-based study. Recently, an important association between low serum uric acid levels at baseline and depression/anxiety was found in patients with Parkinson’s disease, which may suggest a role for uric acid in both presence and progression of mood disorders in Parkinson’s disease. In this follow-up study, we also found high uric acid levels at baseline were protective against developing PSD at 3 months after stroke. A large number of studies in stroke patients have suggested that elevated uric acid levels were associated with good outcomes. Recently, a phase 2 clinical trial with inosine in Parkinson’s disease demonstrated a potential efficacy of increased uric acid on mood disorders as evaluated on the Geriatric Depression Scale.

The exact role of uric acid in the pathophysiology of depression remains unknown. Recently, oxidative stress has gained attention as one of the potential mechanisms in the pathophysiology of depression. Oxidative stress causes damage to lipids, proteins, DNA, and mitochondria and eventually causes neurotoxicity and neurodegeneration in major depression. Moreover, oxidative stress is closely associated with the inflammatory response. Expression of pro-inflammatory cytokines is increased in reaction to oxidative stress and oxidative stress in turn enhances the inflammatory response. Inflammatory response also plays an important role in the pathogenesis of depression. Uric acid has multiple antioxidant roles that include the scavenging of free radicals and reactive oxygen species, in addition to the chelation of transition metals, the suppression of the Fenton reaction, and the prevention of lipid peroxidation. Furthermore, uric acid is capable of suppressing inflammatory cascade, decreasing blood–brain barrier permeability, and diminishing central nervous tissue damage and neuronal death. Therefore, one of the mechanisms linking uric acid to depression is the neuroprotective effect of uric acid via providing a defense against oxidative stress.

Acute ischemic stroke triggers overproduction of free radicals and reactive oxygen species in ischemic brain tissue and facilitates lipid peroxidation, mitochondrial dysfunction, excitotoxicity, and inflammatory response. As a result, pro-inflammatory cytokines, matrix metalloproteinases, and endothelial adhesion molecules are produced, which may further amplify oxidative stress and brain tissue damage. In acute stage of stroke, uric acid may exert antioxidant protection against free radical damage. A large number of studies have shown a negative correlation between serum uric acid levels and stroke outcomes. A recent animal study demonstrated that uric acid administered after thromboembolic stroke is neuroprotective in the rat brain and it strengthens the benefits of recombinant tissue plasminogen activator. More recently, a randomized clinical trial showed that uric acid therapy was related to a decrease in glucose-driven oxidative stress and improved outcome in patients with hyperglycemia in acute stage. Therefore, given its involvement in stroke as well as depression, uric acid may play an important role in the development of PSD.

We found that physical disability measured by mRS at discharge was a risk factor of the development of PSD, which broadly agrees with the findings of previous studies. Our results also demonstrated that female gender was independently associated with PSD. A pooled estimate also indicates that PSD is slightly more common among women than men. We did not detect any significant association between the development of PSD and other potential variables, including lesion location and NHISS scores, although previous studies have provided conflicting findings on these aspects.

There are several limitations in the present study. First, the fairly rigid inclusion criteria resulted in a relatively small sample size and, in turn, reduced the statistical power of the study. Second, both patients with severe aphasia and patients who died before the 3-month follow-up were not included, which might make us underestimate the actual prevalence of PSD. Third, serum levels of uric acid were measured only 1 time at admission, further studies are needed to evaluate how uric acid levels at admission are associated with the development of PSD.
acid levels change across time following stroke and whether its levels increased at later points improve stroke outcomes. Lastly, the study subjects were not randomly selected and came from only 1 clinic. Therefore, our results may not be readily generalized to other Chinese patients. Further research is needed.

In summary, in spite of these limitations, our study demonstrates an important association between serum uric acid levels at admission and the development of PSD at 3 months after stroke. Further studies on larger populations should be encouraged to confirm this association, which may provide novel proposal for the prevention of PSD, the treatment of PSD, or both.

REFERENCES

1. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9:1017–1025.

2. Schmid AA, Kroenke K, Hendrie HC, et al. Poststroke depression and treatment effects on functional outcomes. Neurology. 2011;76:1000–1005.

3. Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke. 2007;38:1860–1863.

4. Ayerbe L, Aysis S, Wolfe CD, et al. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:14–21.

5. Yuan HW, Wang CX, Zhang N, et al. Poststroke depression and risk of recurrent stroke at 1 year in a Chinese cohort study. PLoS ONE. 2012;7:e6906.

6. Black CN, Bot M, Scheffer PG, et al. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology. 2015;51:164–175.

7. Maes M, Galecki P, Chang YS, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:676–692.

8. Holme I, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266:558–570.

9. Kawai T, Ohishi M, Takeya Y, et al. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertension Res. 2012;35:1087–1092.

10. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–6862.

11. Wen S, Cheng M, Wang H, et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem. 2012;45:49–53.

12. Chaudhari K, Khanzode S, Khanzode S, et al. Clinical correlation of alteration of endogenous antioxidant-uric acid level in major depressive disorder. Indian J Clin Biochem. 2010;25:77–81.

13. Lyngdoh T, Bochud M, Glauj J, et al. Associations of serum uric acid and SLC2A9 variant with depressive and anxiety disorders: a population-based study. PLoS ONE. 2013;8:e76336.

14. Cojocaru IM, Cojocaru M, Sapira V, et al. Evaluation of oxidative stress in patients with acute ischemic stroke. Rom J Intern Med. 2013;51:97–106.

15. Cherubini A, Ruggiero C, Polidori MC, et al. Potential markers of oxidative stress in stroke. Free Radical Biol Med. 2005;39:841–852.

16. Nabavi SF, Dean OM, Turner A, et al. Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols? Curr Med Chem. 2015;22:343–351.

17. Wu H, Jia Q, Liu G, et al. Decreased uric acid levels correlate with poor outcomes in acute ischemic stroke patients, but not in cerebral hemorrhage patients. J Stroke Cerebrovasc Dis. 2014;23:469–475.

18. Chiquete E, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al. Serum uric acid and outcome after acute ischemic stroke: PREMIER study. Cerebrovasc Dis. 2013;35:168–174.

19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

20. Kuzuya M, Ando F, Iguchi A, et al. Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol Ser A Biol Sci Med Sci. 2002;57:M660–M664.

21. Mehrpour M, Khuzran M, Najimi N, et al. Serum uric acid level in acute stroke patients. Med J Islam Repub Iran. 2012;26:66–72.

22. Brouns R, Wauters A, Van De Vijver G, et al. Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. Clin Chem Lab Med. 2010;48:383–390.

23. Hong JM, Bang OY, Chung CS, et al. Influence of recanalization on uric acid patterns in acute ischemic stroke. Cerebrovasc Dis. 2010;29:431–439.

24. Bove M, Canevelli L, Cicero AF, et al. Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health. 2010;14:801–806.

25. Moccia M, Picillo M, Erro R, et al. Influence of aging and cancer: a hypothesis. J Gerontol Ser A Biol Sci Med Sci. 2002;57:M660–M664.

26. Parkinson Study Group S-PDISchwarzschild MA, Ascherio A, et al. Insomnie to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71:141–150.

27. Maes M, Mihaylova I, Kubera M, et al. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuroendocrinol Lett. 2009;30:715–722.

28. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–817.

29. Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851–876.

30. Nizzumo K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem. 2009;109(Suppl 1):133–138.

31. Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:760–768.

32. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007;6:662–680.

33. Squadrino GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376:333–337.

34. Lucca G, Comim CM, Valvassori SS, et al. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J Psychiatr Res. 2009;43:864–869.

35. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radical Biol Med. 2002;33:1363–1371.
36. Sugawara T, Chan PH. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. *Antioxid Redox Signal.* 2003;5:597–607.

37. Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. *Stroke.* 2002;33:1048–1052.

38. Romanos E, Planas AM, Amaro S, et al. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. *J Cereb Blood Flow Metab.* 2007;27:14–20.

39. Amaro S, Llull L, Renu A, et al. Uric acid improves glucose-driven oxidative stress in human ischemic stroke. *Ann Neurol.* 2015;77:775–783.

40. Zhang WN, Pan YH, Wang XY, et al. A prospective study of the incidence and correlated factors of post-stroke depression in China. *PLoS ONE.* 2013;8:e78981.

41. Poynter B, Shuman M, Diaz-Granados N, et al. Sex differences in the prevalence of post-stroke depression: a systematic review. *Psychosomatics.* 2009;50:563–569.